2. Antibodies
  3. Primary Antibodies
  4. Monoclonal Antibodies Recombinant Antibodies
  5. Quinolones Antibody (YA903)(PBS only)

Quinolones Antibody (YA903)(PBS only)

Cat. No.: HY-P81060
User Guide for Antibodies Technical Support

Quinolones Antibody (YA903) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Quinolones.

For research use only. We do not sell to patients.

Size Stock
50 μL   Get quote  
100 μL   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • WB: Western Blot;
  • IHC-P: Immunohistochemistry-Paraffin;
  • IHC-F: Immunohistochemistry-Frozen;
  • ICC/IF: Immunocytochemistry/Immunofluorescence;
  • IF-Tissue: Immunofluorescence-Tissue;
  • mIHC: Multiplex Immunohistochemical;
  • IP: Immunoprecipitation;
  • ChIP: Chromatin Immunoprecipitation;
  • FC: Flow Cytometry;
  • ELISA: Enzyme Linked Immunosorbent Assay

  • Product Detail

  • Background

  • Documentation

  • References

Description

Quinolones Antibody (YA903) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Quinolones.
Host

Rabbit
Clonality

Recombinant,Monoclonal
Species Reactivity
Species independent
SwissProt ID

Gene ID
Immunogen

Chemical/ Small Molecule corresponding to Quinolones conjugated to OVA.
Application &
Dilution Ratio
Application Dilution Ratio
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
1:5000
Sensitivity Endogenous Purity Affinity Purified
Conjugation Non-conjugated Modification Unmodified
Isotype IgG  
Appearance

Liquid
Formulation

Supplied in PBS (pH7.4).
Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
Shipping

Shipping with blue ice.
Background
Function：Quinolones are synthetic antimicrobials based on the 4-oxo-1,4-dihydroquinolone skeleton, developed in the early 1960s; two decades later, fluoroquinolones were designed with a broader antimicrobial spectrum and good oral absorption. The first-generation quinolones, such as nalidixic and oxolinic acids, act against Gram-negative bacteria and are used to treat urinary tract infections. The second-generation quinolones are fluoroquinolones (e.g., enrofloxacin, danofloxacin, ciprofloxacin) containing a fluorine atom at position 6 and a bulky piperidine at position 7, broadening the antimicrobial spectrum to Pseudomonas species and some Gram-positive organisms like Staphylococcus aureus. They are active against aerobic Gram-negative bacilli, particularly enterobacteriaceae, Haemophilus, and pseudomonadaceae, with therapeutic indications including urinary tract infections, prostatitis, gastrointestinal and abdominal infections, as well as prophylaxis and therapy of "traveller’s disease" and other severe gastrointestinal diseases. In livestock, they show high activity against a wide range of diseases; in the EU, seven quinolones (danofloxacin, difloxacin, enrofloxacin, flumequine, marbofloxacin, oxolinic acid, sarafloxacin) are approved for use in food-producing animals, with maximum residue limits (MRLs) in meat matrices varying by drug and tissue. Their mechanism of action involves converting target topoisomerases (gyrase and topoisomerase IV) into toxic enzymes that fragment the bacterial chromosome, or forming reversible drug–enzyme–DNA complexes with these two enzymes, blocking DNA replication and RNA synthesis to inhibit bacterial growth and kill bacteria rapidly, with rapid lethal action proposed to arise from the release of DNA breaks from the complexes. Bacteria acquire resistance to quinolones through mutations and/or altered expression of target proteins (gyrase and topoisomerase IV)， drug permeability proteins, drug efflux proteins, and gyrase-protecting proteins, as well as via plasmid-mediated quinolone resistance (PMQR) mechanisms; resistance is acquired spontaneously and through quinolone-mediated induction of the mutagenic SOS response, with selective enrichment of mutants strongly dependent on quinolone concentration, and the mutant prevention concentration (MPC) serving as a measure of antimutant activity. They have a high safety profile with rare serious side effects including QTc elongation, hepatotoxicity, and tendon rupture, and can also perturb mitochondrial functions, which can be reduced by antioxidants. Extensive use in humans and animals has led to the rapid emergence of resistance, with rare and scattered data from Arab countries; understanding the prevalence and distribution of PMQR is essential to stop the irrational use of quinolones in these regions.
Synonyms
Quinolones antibody
Documentation
User Guide for Antibodies (1077 KB)
References

Quinolones Antibody (YA903)(PBS only) Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Quinolones Antibody (YA903)(PBS only)
Cat. No.:
HY-P81060
Quantity:
MCE Japan Authorized Agent:

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Country or Region *

Email Address *

     

Phone Number *

 

Organization Name *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.